Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO

BACKGROUND: Patients’ experience of symptoms often goes undetected during consultation in an outpatient clinic, and the use of a patient-reported outcome measure (PRO) in such a setting could be useful to aid treatment decision-making. A new PRO measure, the HM-PRO (Hematological Malignancy Specific...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Pharmacol
Autors principals: Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Al-Obaidi, Magda J., Oblak, Metod, Salek, Sam
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7606444/
https://ncbi.nlm.nih.gov/pubmed/33192513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.571066
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars